Klein-Brill, Avital
Amar-Farkash, Shlomit
Rosenberg-Katz, Keren
Brenner, Ronen
Becker, Jürgen C.
Aran, Dvir
Article History
Received: 23 October 2023
Revised: 14 December 2023
Accepted: 16 January 2024
First Online: 13 February 2024
Competing interests
: AK-B reported employment as a researcher in Carelon Digital Platforms Israel, Ltd, during the conduct of the study. SA-F reported employment as a researcher in Carelon Digital Platforms Israel, Ltd, during the conduct of the study. DA reported receiving consulting fees from Carelon Digital Platforms Israel, Ltd. KR-K reported employment as a researcher in Carelon Digital Platforms Israel, Ltd, during the conduct of the study. JCB has received speaker, advisory board and/or consulting honoraria from Almirall, Amgen, Merck Serono, Pfizer, Recordati and Sanofi; advisory board honoraria from 4SC, Amgen, Merck Ser-ono, Novartis and ReProTher; and research funding from Alce-dis, Boehringer Ingelheim, Bristol Myers Squibb, IQVIA and Merck Serono.
: This study was designed as an analysis of medical claims data. Therefore, there was no active recruitment, enrollment, or follow-up of study participants; no data were collected directly from individuals. Thus, there was no need to obtain additional IRB approval because the HIPAA Privacy Rule permits the use or disclosure of protected health information (PHI) in a limited data set for research without individual authorization, provided certain criteria are met.